PARP inhibitorPhase 3 trialInvestigational
Capivasertib
How it works
Blocks the activity of the PARP protein, which is involved in the repair of DNA damage in cancer cells.
Cancer types
Lung Cancer— All patients
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Capivasertib and Fulvestrant vs Placebo in Advanced Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| New Cancer Treatment's Cost-Effectiveness Questioned | Breast Cancer | phase-3 | Capivasertib plus fulvestrant yielded more quality-adjusted life-years (1.89 vs. 1.29) and life years (3.31 vs. 2.49) than fulvestrant alone. | Source → |
| New Treatment Option for Advanced Breast Cancer | Breast Cancer | review | — | Source → |
| Capivasertib and Abiraterone for Prostate Cancer with PTEN Deficiency | Prostate Cancer | phase-3 | — | Source → |
| Capivasertib and Fulvestrant for Advanced or Metastatic Breast Cancer in Chinese Patients | Breast Cancer | phase-3 | — | Source → |
| Researchers Explore New Treatment for Lung Cancer Resistance | Lung Cancer | lab-study | — | Source → |
| Researchers Identify Resistance Mutations in Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Combining Two Cancer Drugs May Help Overcome Resistance in Melanoma | Melanoma | lab-study | Tumor volumes in the capivasertib-vemurafenib and capivasertib-encorafenib groups were reduced by ~70% relative to control. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.